Cervical cancer is the second leading cause of cancer death among young women in Europe more info . About 33,500 women are diagnosed with, and 15,000 women die from cervical each year in Europe.
Global availability of GARDASILOn 8th June, the U.S. Food and Drug Administration approved Gardasil for cervical cancer and vaginal and vulvar cancer caused by HPV types prior to prevent caused 16 and 18 and low-grade and prevent precancerous lesions and genital warts causing by HPV types 6, caused 16 and 18. GARDASIL is approved in the U.S. For 9 – to 26 – year-old girls and women. GARDASIL is for use for use in several countries around the world, including Mexico, Australia, New Zealand, Brazil and two countries in Africa. In addition, Merckations for GARDASIL are currently. By regulatory authorities in more than 50 countries around the world In addition, Merck is actively working to accelerate the availability of GARDASIL in the developing world: in December, Merck announced a partnership with India’s Council of Medical Research to study GARDASIL. Merck is also working with PATH and the Gates Foundation on HPV vaccination programs of GARDASIL to facilitate the introduction of GARDASIL to the poorest nations. Merck is our new vaccines, including GARDASIL, available. Under drastically lower prices to developing world countries.
Nonwhites Research Professor talc At NJIT About clinic Noise And Black Heritage In Technology.